 Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
| Descriptor ID |
D018124
|
| MeSH Number(s) |
D12.776.543.750.705.852.760
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- Antigens, CD137
- Antigens, CD27
- Antigens, CD30
- Antigens, CD40
- Antigens, CD95
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- Glucocorticoid-Induced TNFR-Related Protein
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 2 | 2 | 4 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2016 | 2 | 0 | 2 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Lopez-Silva C, Surapaneni A, Coresh J, Reiser J, Parikh CR, Obeid W, Grams ME, Chen TK. Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):350-360.
-
Barua A, Edassery SL, McNeal S, Bahr JM, Bitterman P, Basu S, Sharma S, Abramowicz JS. Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer. Int J Gynecol Cancer. 2016 10; 26(8):1375-85.
-
McNeal S, Bitterman P, Bahr JM, Edassery SL, Abramowicz JS, Basu S, Barua A. Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model. J Immunol Res. 2016; 2016:6729379.
-
Pradere JP, Kluwe J, De Minicis S, Jiao JJ, Gwak GY, Dapito DH, Jang MK, Guenther ND, Mederacke I, Friedman R, Dragomir AC, Aloman C, Schwabe RF. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013 Oct; 58(4):1461-73.
-
Gan J, Manadan AM, Sequiera W, Block JA. Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther. 2013 Jan; 20(1):73-8.
-
Richards MH, Getts MT, Podojil JR, Jin YH, Kim BS, Miller SD. Virus expanded regulatory T cells control disease severity in the Theiler's virus mouse model of MS. J Autoimmun. 2011 Mar; 36(2):142-54.
-
Kalayjian RC, Machekano RN, Rizk N, Robbins GK, Gandhi RT, Rodriguez BA, Pollard RB, Lederman MM, Landay A. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
-
Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol. 2009 May; 36(5):914-7.
-
Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90.
-
Manadan AM, Joyce K, Sequeira W, Block JA. Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):743-5.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|